2020 American Society of Hematology (ASH) Annual Meeting
Research findings from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting, to be held virtually Dec. 5 – 8, 2020.* With more than 18,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.
Use #ASH20 to follow and share on Twitter.
Following the ASH Presidential Symposium on Tues., Dec. 8, Jane Winter, MD, will begin successive one-year terms as president - elect and president. An ASH member for more than 30 years, Dr. Winter is a professor of Medicine in the Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine, and currently serves as vice president of ASH. Her research focus includes clinical and biological markers of prognosis in diffuse large B-cell lymphoma, as well as clinical trials and translational research with novel agents for non-Hodgkin and Hodgkin lymphoma.
As leaders in the research and treatment of blood cancers, Lurie Cancer Center and Northwestern Medicine’s physicians and scientists will present exciting new research and important clinical findings throughout the meeting. Presenting authors and investigators who will be leading sessions include:
Saturday, December 5
|
10:45 AM CST Barbara Pro, MD Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial |
|
2:15 PM CST Alexis Thompson, MD Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia |
|
2:45 PM CST Adam Yuh Lin, MD, PhD In Situ Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model |
|
4:30 PM CST Yazan Numan, MD Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors |
|
9:00 AM – 5:30 PM CST William Pearse, MD Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review Perceptions of Financial and Psychosocial Burden Among Patients with Hematologic Malignancies Treated with Novel Oral Antineoplastic Agents |
|
9:00 AM – 5:30 PM CST Carlos Galvez, MD A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen |
Sunday, December 6
|
5:15 PM CST Brady L. Stein Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study |
|
9:00 AM – 5:30 PM CST Jessica Altman, MD Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation |
|
9:00 AM – 5:30 PM CST Carlos Galvez, MD Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience |
|
9:00 AM – 5:30 PM CST Jenn Miller, PharmD Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens |
Monday, December 7
|
3:30 PM CST Alexis Thompson, MD Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy |
|
9:00 AM – 5:30 PM CST Reem Karmali, MD Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease |
*Friday, December 4
|
10:00 AM CST Jessica Altman, MD, and William Pearse, MD Press Briefing on Disparities in Health Care: Diversity, Equity and Inclusion (DEI) The Role of Structural Violence in Acute Myeloid Leukemia Outcomes |